Agios Pharmaceuticals Attracts Leading Cancer Metabolism Experts to Advisory Team
Drs Chi Dang, Joshua Rabinowitz, Clary Clish, Matthew Vander Heiden and James Bradner Bring Deep Biology and Metabolomic Experience from Leading Laboratories
Cambridge, MA – November 24, 2008 – Agios Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel
drugs in the rapidly emerging field of cancer metabolism, announced today the appointments of several leading scientific advisors:
Agios Pharmaceuticals Expands Into 21,000 SqFt Facility
Creates Largest Research Laboratory Dedicated to Cancer Metabolism
Cambridge, MA – November 24, 2008 – Agios Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, announced today that it has leased a 21,000 square-foot facility in Cambridge. This new facility creates the world’s largest laboratory dedicated to cancer metabolism research.
Terry Newendorp Joins Ze-gen’s Board of Directors
Boston, MA – December 18, 2008 Ze-gen, Inc., a clean energy company providing advanced gasification technology to convert waste streams into synthesis gas, is pleased to announce the addition of Terry Newendorp to its Board of Directors.
Helicos BioSciences Corporation Announces Pricing of Common Stock and Warrant Private Placement
CAMBRIDGE, Mass., Dec 19, 2008 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets, today announced that it has entered into a definitive agreement with certain investors to raise approximately $18.6 million in gross proceeds in a private placement through the sale of shares of its common stock and warrants.
Ze-gen Secures $20 Million in Funding to Deploy Technology
Boston, MA – January 13, 2009 Ze-gen, Inc., which has developed commercially viable gasification technology for converting waste streams into synthesis gas, today announced that it has raised $20 million in Series B financing. The funds will be used to commercially deploy Ze-gen's technology.
Helicos Announces Improved Performance of Its HeliScope(TM) Single Molecule Sequencer
30GB of High-Quality Data at 150MB per Hour Throughput Equivalent to 5 to 10 Human Genomes is Industry Best
Black Duck Software Closes $9.5 Million in Financing
Capping year of solid growth, company will use funds for product enhancements and international expansion
Software Industry Veteran Tim Yeaton Named New CEO of Black Duck Software
Track record in open source software, successful partnerships and acquisitions strengthens Black Duck leadership position
Oasys Closes $10 Million Financing
Developing ultra-low cost seawater desalination and water treatment
Selecta Biosciences, Inc. Closes $15.1M Series B Financing
WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a privately held biopharmaceutical company developing immunomodulatory nanoparticles for the treatment and prevention of human diseases, announced today that it has secured a $15.1M Series B financing. Existing investors, Polaris Venture Partners and Flagship Ventures were joined by NanoDimension and Professor Timothy A. Springer. “I am pleased by the strength of our investors whose track record of creating successful companies is a loud validation of our team, technology platform, and product opportunities” said Dr.